Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zibotentan PK in Hepatic and Renal Impairment
NCT05112419Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zibotentan in chronic kidney disease (CKD) (2 arms), sponsored by AstraZeneca. Primary endpoints: Area under plasma concentration-time curve from time zero to infinity, Area under the plasma concentration-curve from time zero to time of last quantifiable concentration and 1 more. Started Nov 2021; status: completed.
02
Drugs
zibotentan
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05112419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05112419.